Last 12 months
Inside the activity.
6 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 3 | 2 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 3 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 15, 2025 Filed Aug 19, 2025 20:51 UTC |
Versant Venture Capital VI, L.P.10% owner
Versant Ventures VI GP, L.P.10% owner
Versant Ventures VI GP-GP, LLC10% owner
Versant Vantage II, L.P.10% owner
Versant Vantage II GP, L.P.10% owner
Versant Vantage II GP-GP, LLC10% owner
Versant Venture Capital VII, L.P.10% owner
Versant Ventures VII GP, L.P.10% owner
Versant Ventures VII GP-GP, LLC10% owner
|
SaleCommon Stock | 69,949 | $39.50 | $2,762,985.50 |
DisclosureSEC source: 0000950170-25-110163 · ownership.xml · nonDerivative · entry 2 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 977,963 F2 · ownership.nature: These shares are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 20:51 UTC |
Versant Venture Capital VI, L.P.10% owner
Versant Ventures VI GP, L.P.10% owner
Versant Ventures VI GP-GP, LLC10% owner
Versant Vantage II, L.P.10% owner
Versant Vantage II GP, L.P.10% owner
Versant Vantage II GP-GP, LLC10% owner
Versant Venture Capital VII, L.P.10% owner
Versant Ventures VII GP, L.P.10% owner
Versant Ventures VII GP-GP, LLC10% owner
|
SaleCommon Stock | 145,051 | $39.50 | $5,729,514.50 |
DisclosureSEC source: 0000950170-25-110163 · ownership.xml · nonDerivative · entry 1 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,430,848 F1 · ownership.direct: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| July 10, 2025 Filed Jul 14, 2025 20:50 UTC |
Versant Venture Capital VI, L.P.10% owner
Versant Ventures VI GP, L.P.10% owner
Versant Ventures VI GP-GP, LLC10% owner
Versant Vantage II, L.P.10% owner
Versant Vantage II GP, L.P.10% owner
Versant Vantage II GP-GP, LLC10% owner
Versant Venture Capital VII, L.P.10% owner
Versant Ventures VII GP, L.P.10% owner
Versant Ventures VII GP-GP, LLC10% owner
|
SaleCommon Stock | 191,376 | $34.00 | $6,506,784.00 |
DisclosureSEC source: 0000950170-25-095616 · ownership.xml · nonDerivative · entry 1 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,575,899 F1 · ownership.direct: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| June 27, 2025 Filed Jul 1, 2025 22:16 UTC |
Versant Venture Capital VI, L.P.10% owner
Versant Ventures VI GP, L.P.10% owner
Versant Ventures VI GP-GP, LLC10% owner
Versant Vantage II, L.P.10% owner
Versant Vantage II GP, L.P.10% owner
Versant Vantage II GP-GP, LLC10% owner
Versant Venture Capital VII, L.P.10% owner
Versant Ventures VII GP, L.P.10% owner
Versant Ventures VII GP-GP, LLC10% owner
|
SaleCommon Stock | 200,000 | $30.47 | $6,093,000.00 |
DisclosureSEC source: 0000950170-25-092373 · ownership.xml · nonDerivative · entry 1 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,767,275 F1 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $30.18 to $30.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · ownership.direct: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| June 20, 2025 Filed Jun 20, 2025 21:50 UTC |
Versant Venture Capital VI, L.P.10% owner
Versant Ventures VI GP, L.P.10% owner
Versant Ventures VI GP-GP, LLC10% owner
Versant Vantage II, L.P.10% owner
Versant Vantage II GP, L.P.10% owner
Versant Vantage II GP-GP, LLC10% owner
Versant Venture Capital VII, L.P.10% owner
Versant Ventures VII GP, L.P.10% owner
Versant Ventures VII GP-GP, LLC10% owner
|
SaleCommon Stock | 133,924 | $30.25 | $4,051,201.00 |
DisclosureSEC source: 0000950170-25-088604 · ownership.xml · nonDerivative · entry 3 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,967,275 F2 · ownership.direct: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| June 20, 2025 Filed Jun 20, 2025 21:50 UTC |
Versant Venture Capital VI, L.P.10% owner
Versant Ventures VI GP, L.P.10% owner
Versant Ventures VI GP-GP, LLC10% owner
Versant Vantage II, L.P.10% owner
Versant Vantage II GP, L.P.10% owner
Versant Vantage II GP-GP, LLC10% owner
Versant Venture Capital VII, L.P.10% owner
Versant Ventures VII GP, L.P.10% owner
Versant Ventures VII GP-GP, LLC10% owner
|
SaleCommon Stock | 100,877 | $30.35 | $3,061,616.95 |
DisclosureSEC source: 0000950170-25-088604 · ownership.xml · nonDerivative · entry 2 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,047,912 F1 · ownership.nature: These shares are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 21:50 UTC |
Versant Venture Capital VI, L.P.10% owner
Versant Ventures VI GP, L.P.10% owner
Versant Ventures VI GP-GP, LLC10% owner
Versant Vantage II, L.P.10% owner
Versant Vantage II GP, L.P.10% owner
Versant Vantage II GP-GP, LLC10% owner
Versant Venture Capital VII, L.P.10% owner
Versant Ventures VII GP, L.P.10% owner
Versant Ventures VII GP-GP, LLC10% owner
|
SaleCommon Stock | 100,000 | $29.95 | $2,995,000.00 |
DisclosureSEC source: 0000950170-25-088604 · ownership.xml · nonDerivative · entry 1 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,148,789 F1 · ownership.nature: These shares are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| June 11, 2025 Filed Jun 11, 2025 21:45 UTC |
Scheiner ZacharyDirector
|
GrantStock Option (right to buy) · Derivative | 13,500 | $0.00 Strike: $30.00 | $0.00 |
DisclosureSEC source: 0001815776-25-000043 · wk-form4_1749678343.xml · derivative · entry 1 Scheiner Zachary · CIK 0001816523 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 13,500 shares Expires 2035-06-10 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on June 11, 2026. F2 · ownership.direct: Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), the RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund II and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying common stock. Read SEC document |
| June 11, 2025 Filed Jun 11, 2025 21:46 UTC |
George Jeffrey P.Director
|
GrantStock Option (right to buy) · Derivative | 13,500 | $0.00 Strike: $30.00 | $0.00 |
DisclosureSEC source: 0001815776-25-000048 · wk-form4_1749678400.xml · derivative · entry 1 George Jeffrey P. · CIK 0001796789 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 13,500 shares Expires 2035-06-10 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on June 11, 2026. Read SEC document |
| June 11, 2025 Filed Jun 11, 2025 23:43 UTC |
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
RA Capital Nexus Fund II, L.P.Director
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
|
GrantStock Option (right to buy) · Derivative | 13,500 | $0.00 Strike: $30.00 | $0.00 |
DisclosureSEC source: 0001415889-25-016757 · form4-06112025_110656.xml · derivative · entry 1 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 13,500 Underlying: Common Stock · 13,500 shares Expires 2035-06-10 F1 · derivative.exercise_date: Represents the grant of a stock option to Zachary Scheiner pursuant to the Issuer's Outside Director Compensation Policy (the "Policy"). One hundred percent (100%) of the shares subject to the option shall vest on June 11, 2026, subject to Dr. Scheiner's continuing to be an Outside Director (as defined in the Policy) through such applicable date. F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund II, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of its or his pecuniary interest therein. F3 · ownership.nature: Under Dr. Scheiner's arrangement with the Adviser, Dr. Scheiner holds the option for the benefit of the Fund, the Nexus Fund II and the Account. Dr. Scheiner is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund II and the Account to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock. Read SEC document |
| June 11, 2025 Filed Jun 11, 2025 21:46 UTC |
Drapkin Kimberlee CDirector
|
GrantStock Option (right to buy) · Derivative | 13,500 | $0.00 Strike: $30.00 | $0.00 |
DisclosureSEC source: 0001815776-25-000047 · wk-form4_1749678389.xml · derivative · entry 1 Drapkin Kimberlee C · CIK 0001340881 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 13,500 shares Expires 2035-06-10 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on June 11, 2026. Read SEC document |
| June 11, 2025 Filed Jun 11, 2025 21:46 UTC |
Guerard FredericDirector
|
GrantStock Option (right to buy) · Derivative | 13,500 | $0.00 Strike: $30.00 | $0.00 |
DisclosureSEC source: 0001815776-25-000046 · wk-form4_1749678377.xml · derivative · entry 1 Guerard Frederic · CIK 0001825009 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 13,500 shares Expires 2035-06-10 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on June 11, 2026. Read SEC document |
| June 11, 2025 Filed Jun 11, 2025 21:46 UTC |
MCCOLLUM JAMES WDirector
|
GrantStock Option (right to buy) · Derivative | 13,500 | $0.00 Strike: $30.00 | $0.00 |
DisclosureSEC source: 0001815776-25-000044 · wk-form4_1749678354.xml · derivative · entry 1 MCCOLLUM JAMES W · CIK 0001200889 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 13,500 shares Expires 2035-06-10 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on June 11, 2026. Read SEC document |
| June 11, 2025 Filed Jun 11, 2025 21:46 UTC |
Thunen Shelley BDirector
|
GrantStock Option (right to buy) · Derivative | 13,500 | $0.00 Strike: $30.00 | $0.00 |
DisclosureSEC source: 0001815776-25-000045 · wk-form4_1749678366.xml · derivative · entry 1 Thunen Shelley B · CIK 0001297491 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 13,500 shares Expires 2035-06-10 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on June 11, 2026. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:37 UTC |
Versant Venture Capital VI, L.P.10% owner
Versant Ventures VI GP, L.P.10% owner
Versant Ventures VI GP-GP, LLC10% owner
Versant Vantage II, L.P.10% owner
Versant Vantage II GP, L.P.10% owner
Versant Vantage II GP-GP, LLC10% owner
Versant Venture Capital VII, L.P.10% owner
Versant Ventures VII GP, L.P.10% owner
Versant Ventures VII GP-GP, LLC10% owner
|
SaleCommon Stock | 350,000 | $29.00 | $10,150,000.00 |
DisclosureSEC source: 0000950170-25-085490 · ownership.xml · nonDerivative · entry 1 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,248,789 F1 · ownership.nature: These shares are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| April 09, 2025 Filed Apr 9, 2025 19:20 UTC |
Olsson ShawnChief Commercial Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 1,400 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001815776-25-000022 · wk-form4_1744240821.xml · derivative · entry 2 Olsson Shawn · CIK 0002015796 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,241 Underlying: Common Stock · 1,400 shares Expires 2031-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Shares issued pursuant to the LENZ Therapeutics Operations, Inc. (previously named Lenz Therapeutics, Inc.) 2020 Equity Incentive Plan (the "2020 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2020 Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean April 26, 2021. Read SEC document |
| April 09, 2025 Filed Apr 9, 2025 19:20 UTC |
Olsson ShawnChief Commercial Officer
|
Exercise / conversionCommon Stock | 1,400 | $2.08 | $2,912.00 |
DisclosureSEC source: 0001815776-25-000022 · wk-form4_1744240821.xml · nonDerivative · entry 1 Olsson Shawn · CIK 0002015796 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,733 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 07, 2025 Filed Mar 7, 2025 23:10 UTC |
Schimmelpennink Evert B.Director · President, CEO and Secretary
|
Exercise / conversionStock Option (right to buy) · Derivative | 4,200 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001815776-25-000011 · wk-form4_1741389036.xml · derivative · entry 2 Schimmelpennink Evert B. · CIK 0001713795 · Director · President, CEO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 337,906 Underlying: Common Stock · 4,200 shares Expires 2031-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Shares issued pursuant to the LENZ Therapeutics Operations, Inc. (previously named Lenz Therapeutics, Inc.) 2020 Equity Incentive Plan (the "2020 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2020 Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 8, 2021. Read SEC document |
| March 07, 2025 Filed Mar 7, 2025 23:10 UTC |
Schimmelpennink Evert B.Director · President, CEO and Secretary
|
Exercise / conversionCommon Stock | 4,200 | $1.04 | $4,368.00 |
DisclosureSEC source: 0001815776-25-000011 · wk-form4_1741389036.xml · nonDerivative · entry 1 Schimmelpennink Evert B. · CIK 0001713795 · Director · President, CEO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 09, 2025 Filed Jan 13, 2025 17:24 UTC |
Odrich MarcChief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 80,100 | $0.00 Strike: $26.34 | $0.00 |
DisclosureSEC source: 0001815776-25-000007 · wk-form4_1736807088.xml · derivative · entry 1 Odrich Marc · CIK 0002015900 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,100 Underlying: Common Stock · 80,100 shares Expires 2035-01-08 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean January 9, 2025. Read SEC document |
| January 09, 2025 Filed Jan 13, 2025 17:26 UTC |
Olsson ShawnChief Commercial Officer
|
GrantStock Option (right to buy) · Derivative | 80,100 | $0.00 Strike: $26.34 | $0.00 |
DisclosureSEC source: 0001815776-25-000009 · wk-form4_1736807211.xml · derivative · entry 1 Olsson Shawn · CIK 0002015796 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,100 Underlying: Common Stock · 80,100 shares Expires 2035-01-08 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean January 9, 2025. Read SEC document |
| January 09, 2025 Filed Jan 13, 2025 22:22 UTC |
Chevallard Daniel R.Chief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 70,444 | $0.00 Strike: $26.34 | $0.00 |
DisclosureSEC source: 0001815776-25-000005 · wk-form4_1736806964.xml · derivative · entry 1 Chevallard Daniel R. · CIK 0001706176 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,444 Underlying: Common Stock · 70,444 shares Expires 2035-01-08 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean January 9, 2025. Read SEC document |
| January 09, 2025 Filed Jan 13, 2025 22:20 UTC |
Schimmelpennink Evert B.Director · President, CEO and Secretary
|
GrantStock Option (right to buy) · Derivative | 279,100 | $0.00 Strike: $26.34 | $0.00 |
DisclosureSEC source: 0001815776-25-000003 · wk-form4_1736806836.xml · derivative · entry 1 Schimmelpennink Evert B. · CIK 0001713795 · Director · President, CEO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 279,100 Underlying: Common Stock · 279,100 shares Expires 2035-01-08 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean January 9, 2025. Read SEC document |
| December 16, 2024 Filed Dec 17, 2024 19:55 UTC |
Olsson ShawnChief Commercial Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 3,333 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001815776-24-000074 · wk-form4_1734483323.xml · derivative · entry 2 Olsson Shawn · CIK 0002015796 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,641 Underlying: Common Stock · 3,333 shares Expires 2031-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Shares issued pursuant to the LENZ Therapeutics Operations, Inc. (previously named Lenz Therapeutics, Inc.) 2020 Equity Incentive Plan (the "2020 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2020 Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean April 26, 2021. Read SEC document |
| December 16, 2024 Filed Dec 17, 2024 19:55 UTC |
Olsson ShawnChief Commercial Officer
|
Exercise / conversionCommon Stock | 3,333 | $2.08 | $6,932.64 |
DisclosureSEC source: 0001815776-24-000074 · wk-form4_1734483323.xml · nonDerivative · entry 1 Olsson Shawn · CIK 0002015796 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 22, 2024 Filed Jul 24, 2024 00:16 UTC |
Schimmelpennink Evert B.Director · President, CEO and Secretary
|
Exercise / conversionStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001815776-24-000051 · wk-form4_1721780188.xml · derivative · entry 2 Schimmelpennink Evert B. · CIK 0001713795 · Director · President, CEO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 342,106 Underlying: Common Stock · 45,000 shares Expires 2031-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Shares issued pursuant to the LENZ Therapeutics Operations, Inc. (previously named Lenz Therapeutics, Inc.) 2020 Equity Incentive Plan (the "2020 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2020 Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 8, 2021. Read SEC document |
| July 22, 2024 Filed Jul 24, 2024 00:16 UTC |
Schimmelpennink Evert B.Director · President, CEO and Secretary
|
Exercise / conversionCommon Stock | 45,000 | $1.04 | $46,800.00 |
DisclosureSEC source: 0001815776-24-000051 · wk-form4_1721780188.xml · nonDerivative · entry 1 Schimmelpennink Evert B. · CIK 0001713795 · Director · President, CEO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2024 Filed May 15, 2024 20:13 UTC |
Chevallard Daniel R.Chief Financial Officer
|
PurchaseCommon Stock | 3,188 | $15.68 | $49,987.84 |
DisclosureSEC source: 0001815776-24-000046 · wk-form4_1715803974.xml · nonDerivative · entry 1 Chevallard Daniel R. · CIK 0001706176 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,188 Read SEC document |
| May 13, 2024 Filed May 14, 2024 21:29 UTC |
MCCOLLUM JAMES WDirector
|
PurchaseCommon Stock | 31,332 | $15.99 | $501,092.68 |
DisclosureSEC source: 0001815776-24-000044 · wk-form4_1715722170.xml · nonDerivative · entry 1 MCCOLLUM JAMES W · CIK 0001200889 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By trust Disclosed balance after: 525,565 F1 · price: Represents the weighted average share price of an aggregate total of 31,332 shares purchased in the price range of $15.96 to $16.00 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| March 21, 2024 Filed Mar 25, 2024 20:33 UTC |
Odrich MarcChief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 105,000 | $0.00 Strike: $15.05 | $0.00 |
DisclosureSEC source: 0001815776-24-000021 · wk-form4_1711413205.xml · derivative · entry 3 Odrich Marc · CIK 0002015900 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2034-03-20 F4 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 21, 2024. Read SEC document |
| March 21, 2024 Filed Mar 25, 2024 20:33 UTC |
Odrich MarcChief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 66,472 | $0.00 Strike: $6.04 | $0.00 |
DisclosureSEC source: 0001815776-24-000021 · wk-form4_1711413205.xml · derivative · entry 2 Odrich Marc · CIK 0002015900 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,472 Underlying: Common Stock · 66,472 shares Expires 2033-06-19 F2 · date: Stock option assumed in connection with the closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 14, 2023 (the "Merger Agreement"), by and among the Issuer, Generate Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the issuer, and LENZ Therapeutics Operations, Inc. (previously named Lenz Therapeutics, Inc.), a Delaware corporation ("LENZ OpCo"), in exchange of an outstanding option to purchase shares of LENZ OpCo, pursuant to the terms and conditions of the Merger Agreement. F3 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the LENZ Therapeutics Operations, Inc. (previously named Lenz Therapeutics, Inc.) 2020 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 6, 2023. Read SEC document |
| March 21, 2024 Filed Mar 25, 2024 20:33 UTC |
Odrich MarcChief Medical Officer
|
GrantCommon Stock | 99,599 | $0.00 | $0.00 |
DisclosureSEC source: 0001815776-24-000021 · wk-form4_1711413205.xml · nonDerivative · entry 1 Odrich Marc · CIK 0002015900 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,599 F1 · date: Shares issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 14, 2023 (the "Merger Agreement"), by and among the Issuer, Generate Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the issuer, and LENZ Therapeutics Operations, Inc. (previously named Lenz Therapeutics, Inc.), a Delaware corporation ("LENZ OpCo"), in exchange of outstanding shares of LENZ OpCo, pursuant to the terms and conditions of the Merger Agreement. Read SEC document |
| March 21, 2024 Filed Mar 25, 2024 20:34 UTC |
Olsson ShawnChief Commercial Officer
|
GrantStock Option (right to buy) · Derivative | 105,000 | $0.00 Strike: $15.05 | $0.00 |
DisclosureSEC source: 0001815776-24-000022 · wk-form4_1711413279.xml · derivative · entry 4 Olsson Shawn · CIK 0002015796 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2034-03-20 F4 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 21, 2024. Read SEC document |
| March 21, 2024 Filed Mar 25, 2024 20:34 UTC |
Olsson ShawnChief Commercial Officer
|
GrantStock Option (right to buy) · Derivative | 50,915 | $0.00 Strike: $6.04 | $0.00 |
DisclosureSEC source: 0001815776-24-000022 · wk-form4_1711413279.xml · derivative · entry 3 Olsson Shawn · CIK 0002015796 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,915 Underlying: Common Stock · 50,915 shares Expires 2033-06-19 F1 · date: Stock option assumed in connection with the closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 14, 2023 (the "Merger Agreement"), by and among the Issuer, Generate Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the issuer, and LENZ Therapeutics Operations, Inc. (previously named Lenz Therapeutics, Inc.), a Delaware corporation ("LENZ OpCo"), in exchange of an outstanding option to purchase shares of LENZ OpCo, pursuant to the terms and conditions of the Merger Agreement. F3 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the LENZ Therapeutics Operations, Inc. (previously named Lenz Therapeutics, Inc.) 2020 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 6, 2023. Read SEC document |
| March 21, 2024 Filed Mar 25, 2024 20:34 UTC |
Olsson ShawnChief Commercial Officer
|
GrantStock Option (right to buy) · Derivative | 30,466 | $0.00 Strike: $5.05 | $0.00 |
DisclosureSEC source: 0001815776-24-000022 · wk-form4_1711413279.xml · derivative · entry 2 Olsson Shawn · CIK 0002015796 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,466 Underlying: Common Stock · 30,466 shares Expires 2032-11-23 F1 · date: Stock option assumed in connection with the closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 14, 2023 (the "Merger Agreement"), by and among the Issuer, Generate Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the issuer, and LENZ Therapeutics Operations, Inc. (previously named Lenz Therapeutics, Inc.), a Delaware corporation ("LENZ OpCo"), in exchange of an outstanding option to purchase shares of LENZ OpCo, pursuant to the terms and conditions of the Merger Agreement. F2 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the LENZ Therapeutics Operations, Inc. (previously named Lenz Therapeutics, Inc.) 2020 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean April 26, 2021. Read SEC document |
| March 21, 2024 Filed Mar 25, 2024 20:34 UTC |
Olsson ShawnChief Commercial Officer
|
GrantStock Option (right to buy) · Derivative | 67,974 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001815776-24-000022 · wk-form4_1711413279.xml · derivative · entry 1 Olsson Shawn · CIK 0002015796 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,974 Underlying: Common Stock · 67,974 shares Expires 2031-08-18 F1 · date: Stock option assumed in connection with the closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 14, 2023 (the "Merger Agreement"), by and among the Issuer, Generate Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the issuer, and LENZ Therapeutics Operations, Inc. (previously named Lenz Therapeutics, Inc.), a Delaware corporation ("LENZ OpCo"), in exchange of an outstanding option to purchase shares of LENZ OpCo, pursuant to the terms and conditions of the Merger Agreement. F2 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the LENZ Therapeutics Operations, Inc. (previously named Lenz Therapeutics, Inc.) 2020 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean April 26, 2021. Read SEC document |
| March 21, 2024 Filed Mar 26, 2024 00:40 UTC |
Scheiner ZacharyDirector
|
GrantStock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $15.05 | $0.00 |
DisclosureSEC source: 0001415889-24-009073 · form4-03262024_120359.xml · derivative · entry 1 Scheiner Zachary · CIK 0001816523 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2034-03-20 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, one thirty-sixth (1/36th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 21, 2024. F2 · ownership.direct: Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus II Fund, L.P. (the "Nexus II Fund") and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund, the Nexus II Fund and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock. Read SEC document |
| March 21, 2024 Filed Mar 26, 2024 00:48 UTC |
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
RA Capital Nexus Fund II, L.P.Director · 10% owner
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
|
GrantStock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $15.05 | $0.00 |
DisclosureSEC source: 0001415889-24-009077 · form4-03262024_120321.xml · derivative · entry 9 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director · 10% owner Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2034-03-20 F7 · derivative.exercise_date: One thirty-sixth (1/36th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to Dr. Zach Scheiner continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date. "Vesting Commencement Date" shall mean March 21, 2024. F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F8 · ownership.nature: Under Dr. Scheiner's arrangement with the Adviser, Dr. Scheiner holds the option for the benefit of the Fund and the Nexus Fund II. Dr. Scheiner is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock except to the extent of their pecuniary interest therein. Read SEC document |
| March 21, 2024 Filed Mar 26, 2024 00:48 UTC |
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
RA Capital Nexus Fund II, L.P.Director · 10% owner
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
|
GrantWarrants (Right to Buy) · Derivative | 5,371 | Not disclosed Strike: $10.64 | Not disclosed |
DisclosureSEC source: 0001415889-24-009077 · form4-03262024_120321.xml · derivative · entry 8 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director · 10% owner Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 5,371 Underlying: Common Stock · 5,371 shares Expires 2027-10-30 F6 · price: Received in exchange for warrants of LENZ OpCo pursuant to the Merger Agreement. F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F5 · ownership.nature: These securities are held directly by the Account. Read SEC document |
| March 21, 2024 Filed Mar 26, 2024 00:48 UTC |
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
RA Capital Nexus Fund II, L.P.Director · 10% owner
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
|
GrantWarrants (Right to Buy) · Derivative | 10,580 | Not disclosed Strike: $10.64 | Not disclosed |
DisclosureSEC source: 0001415889-24-009077 · form4-03262024_120321.xml · derivative · entry 7 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director · 10% owner Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 10,580 Underlying: Common Stock · 10,580 shares Expires 2027-10-30 F6 · price: Received in exchange for warrants of LENZ OpCo pursuant to the Merger Agreement. F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F4 · ownership.nature: These securities are held directly by Nexus Fund II. Read SEC document |
| March 21, 2024 Filed Mar 26, 2024 00:48 UTC |
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
RA Capital Nexus Fund II, L.P.Director · 10% owner
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
|
GrantWarrants (Right to Buy) · Derivative | 54,582 | Not disclosed Strike: $10.64 | Not disclosed |
DisclosureSEC source: 0001415889-24-009077 · form4-03262024_120321.xml · derivative · entry 6 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director · 10% owner Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 54,582 Underlying: Common Stock · 54,582 shares Expires 2027-10-30 F6 · price: Received in exchange for warrants of LENZ OpCo pursuant to the Merger Agreement. F2 · ownership.nature: These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Read SEC document |
| March 21, 2024 Filed Mar 26, 2024 00:48 UTC |
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
RA Capital Nexus Fund II, L.P.Director · 10% owner
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
|
PurchaseCommon Stockj | 64,971 | $15.03 | $976,514.13 |
DisclosureSEC source: 0001415889-24-009077 · form4-03262024_120321.xml · nonDerivative · entry 5 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director · 10% owner Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 694,755 F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F4 · ownership.nature: These securities are held directly by Nexus Fund II. Read SEC document |
| March 21, 2024 Filed Mar 26, 2024 00:48 UTC |
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
RA Capital Nexus Fund II, L.P.Director · 10% owner
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
|
PurchaseCommon Stock | 933,038 | $15.03 | $14,023,561.14 |
DisclosureSEC source: 0001415889-24-009077 · form4-03262024_120321.xml · nonDerivative · entry 4 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director · 10% owner Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 3,319,339 F2 · ownership.nature: These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Read SEC document |
| March 21, 2024 Filed Mar 26, 2024 00:48 UTC |
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
RA Capital Nexus Fund II, L.P.Director · 10% owner
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
|
GrantCommon Stock | 164,729 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-009077 · form4-03262024_120321.xml · nonDerivative · entry 3 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director · 10% owner Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 164,729 F1 · price: Received in exchange for equity of LENZ Therapeutics Operations, Inc. ("LENZ OpCo") pursuant to an Agreement and Plan of Merger and Reorganization by and among LENZ OpCo, the Issuer and Generate Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Generate Merger Sub"), as amended (the "Merger Agreement"). Under the terms of the Merger Agreement, on March 21, 2024, Generate Merger Sub merged with and into LENZ OpCo (the "Merger"), with LENZ OpCo surviving the Merger as a wholly-owned subsidiary of the Issuer. F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F5 · ownership.nature: These securities are held directly by the Account. Read SEC document |
| March 21, 2024 Filed Mar 26, 2024 00:48 UTC |
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
RA Capital Nexus Fund II, L.P.Director · 10% owner
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
|
GrantCommon Stock | 694,755 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-009077 · form4-03262024_120321.xml · nonDerivative · entry 2 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director · 10% owner Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 694,755 F1 · price: Received in exchange for equity of LENZ Therapeutics Operations, Inc. ("LENZ OpCo") pursuant to an Agreement and Plan of Merger and Reorganization by and among LENZ OpCo, the Issuer and Generate Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Generate Merger Sub"), as amended (the "Merger Agreement"). Under the terms of the Merger Agreement, on March 21, 2024, Generate Merger Sub merged with and into LENZ OpCo (the "Merger"), with LENZ OpCo surviving the Merger as a wholly-owned subsidiary of the Issuer. F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F4 · ownership.nature: These securities are held directly by Nexus Fund II. Read SEC document |
| March 21, 2024 Filed Mar 26, 2024 00:48 UTC |
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
RA Capital Nexus Fund II, L.P.Director · 10% owner
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
|
GrantCommon Stock | 2,386,301 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-009077 · form4-03262024_120321.xml · nonDerivative · entry 1 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director · 10% owner Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 2,386,301 F1 · price: Received in exchange for equity of LENZ Therapeutics Operations, Inc. ("LENZ OpCo") pursuant to an Agreement and Plan of Merger and Reorganization by and among LENZ OpCo, the Issuer and Generate Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Generate Merger Sub"), as amended (the "Merger Agreement"). Under the terms of the Merger Agreement, on March 21, 2024, Generate Merger Sub merged with and into LENZ OpCo (the "Merger"), with LENZ OpCo surviving the Merger as a wholly-owned subsidiary of the Issuer. F2 · ownership.nature: These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Read SEC document |
| March 21, 2024 Filed Mar 26, 2024 00:42 UTC |
MCCOLLUM JAMES WDirector
|
GrantStock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $15.05 | $0.00 |
DisclosureSEC source: 0001815776-24-000028 · wk-form4_1711413733.xml · derivative · entry 5 MCCOLLUM JAMES W · CIK 0001200889 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2034-03-20 F4 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, one thirty-sixth (1/36th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 21, 2024. Read SEC document |
| March 21, 2024 Filed Mar 26, 2024 00:42 UTC |
MCCOLLUM JAMES WDirector
|
GrantWarrant (right to buy) · Derivative | 6,575 | $0.00 Strike: $10.64 | $0.00 |
DisclosureSEC source: 0001815776-24-000028 · wk-form4_1711413733.xml · derivative · entry 4 MCCOLLUM JAMES W · CIK 0001200889 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By trust Disclosed balance after: 6,575 Underlying: Common Stock · 6,575 shares Expires 2027-10-30 F3 · date: Warrant assumed in connection with the closing of the transactions contemplated by the Merger Agreement, in exchange of an outstanding warrant to purchase shares of LENZ OpCo, pursuant to the terms and conditions of the Merger Agreement. Read SEC document |
| March 21, 2024 Filed Mar 26, 2024 00:42 UTC |
MCCOLLUM JAMES WDirector
|
GrantCommon Stock | 16,633 | $15.03 | $249,992.33 |
DisclosureSEC source: 0001815776-24-000028 · wk-form4_1711413733.xml · nonDerivative · entry 3 MCCOLLUM JAMES W · CIK 0001200889 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By trust Disclosed balance after: 494,233 F2 · shares: Shares issued upon the closing of the private placement financing under the Subscription Agreement by and among the Issuer, the Reporting Person and the other purchasers party thereto, dated as of November 14, 2023, pursuant to which, immediately following the closing of the transactions contemplated by the Merger Agreement, such purchasers purchased an aggregate of 3,559,565 shares of Common Stock at a price of $15.0299 per share for aggregate gross proceeds to the Issuer of approximately $53.5 million, as more fully described in the Issuer's reports filed with the Securities and Exchange Commission. Read SEC document |
| March 21, 2024 Filed Mar 26, 2024 00:42 UTC |
MCCOLLUM JAMES WDirector
|
GrantCommon Stock | 477,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001815776-24-000028 · wk-form4_1711413733.xml · nonDerivative · entry 2 MCCOLLUM JAMES W · CIK 0001200889 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By trust Disclosed balance after: 477,600 F1 · date: Shares issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 14, 2023 (the "Merger Agreement"), by and among the Issuer, Generate Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the issuer, and LENZ Therapeutics Operations, Inc. (previously named Lenz Therapeutics, Inc.), a Delaware corporation ("LENZ OpCo"), in exchange of outstanding shares of LENZ OpCo, pursuant to the terms and conditions of the Merger Agreement. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.